“in situ MCL” is very low risk for the development of classic MCL, however, the acquired alterations in the DNA damage response pathway, such as ataxia-telangiectasia mutated (ATM), or cell cycle checkpoint kinase 2 (CHK2) inactivating mutations may facilitate the development of the tumor [53]. The gene discussed is ATM; the disease is neoplasm.